Aligos Enterprise Value Over E B I T D A from 2010 to 2024
| ALGS Stock | USD 25.51 2.52 10.96% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (3.39) | Current Value (3.56) | Quarterly Volatility 285.44066603 |
Check Aligos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aligos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 834.8 K, Net Interest Income of 1.3 M or Interest Income of 1 M, as well as many indicators such as Price To Sales Ratio of 25.26, Dividend Yield of 0.0 or PTB Ratio of 4.71. Aligos financial statements analysis is a perfect complement when working with Aligos Therapeutics Valuation or Volatility modules.
Aligos | Enterprise Value Over E B I T D A |
Latest Aligos Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Aligos Therapeutics over the last few years. It is Aligos Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aligos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Aligos Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (413.78) | |
| Coefficient Of Variation | (68.98) | |
| Mean Deviation | 264.94 | |
| Median | (634.57) | |
| Standard Deviation | 285.44 | |
| Sample Variance | 81,476 | |
| Range | 631 | |
| R-Value | 0.88 | |
| Mean Square Error | 20,283 | |
| R-Squared | 0.77 | |
| Significance | 0.000018 | |
| Slope | 55.97 | |
| Total Sum of Squares | 1.1M |
Aligos Enterprise Value Over E B I T D A History
About Aligos Therapeutics Financial Statements
Aligos Therapeutics shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Aligos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aligos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aligos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (3.39) | (3.56) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.